OBJECTIVE: From 1987 through 1993, we performed embolizations on 150 patients with cerebral arteriovenous malformations (AVMs) at Sahlgrenska University Hospital. The patients ranged in age from 5 to 70 years (35.5 ± 14.8 yr, mean ± standard deviation) and were selected by neurosurgeons in Scandinavia. We analyzed the risk of complications and late outcome to have a better basis for the decision to perform embolization.
The prevalence of cerebral arteriovenous malformations (AVMs) is stated in various studies to be 0.06 to 0.14% (17, 19) . The incidence has been estimated to be [almost equal to]1 in 100,000 population. The natural course in patients with diagnosed AVMs is described by several authors (6, 7, 24) . The annual risk of cerebral bleeding is considered to be on average 3 to 4% and the mortality [almost equal to]1%. Traditionally, the treatment is surgical or radiotherapeutic intervention. During the 1980s, embolization of AVMs became an alternative therapy, alone or in combination with stereotactic radiation or surgery.
The goal in treatment of AVMs is primarily to eliminate the risk of cerebral bleeding; as far as is currently known, this can be achieved only by eliminating the AVMs. Irrespective of the method, there is a risk of complications, and it is important to determine this risk. With surgical intervention, the size and location of the AVMs are the most important prognostic factors (14) .
Stereotactic radiation therapy is thought to carry a low risk of complications but is an alternative only when the volume of the AVMs is <10 cc (27) . Embolization of AVMs is associated with approximately the same incidence and level of complications as is surgical intervention (15) .
Lasjaunias et al. (22) reported that in a review of embolized AVMs with Spetzler-Martin Grades 1 through 3 (26) , severe complications occurred in 5.2% and death in 2.0% of patients (1-3, 9, 10) . In a study by Hurst et al. (16) , endovascular treatment of deep central AVMs resulted in complications in 14.3% of patients.
The aims of this embolization study were as follows: 1) to describe the grade and frequency of complications; 2) to analyze the influence of embolization on bleeding incidents; 3) to examine the effect of treatment on headache, epilepsy, neurasthenic, and focal symptoms; and 4) to estimate late outcome for fully and partially treated patients (see Patients and Methods). With experience, this study will be supplemented by discussions of the indications for treatment of AVMs.
PATIENTS AND METHODS
From 1987 through 1993, 150 patients underwent embolization for AVMs at Sahlgrenska University Hospital. Most patients were referred by neurosurgeons in Scandinavian hospitals and had AVMs that were regarded as unsuitable for surgical or stereotatic radiation treatment. During those years, an additional 34 patients with AVMs were rejected for the following reasons: 1) the AVM was considered impossible to embolize (10 patients), 2) the clinical gain was judged to be less than the risk of complications (6 patients), 3) the patient wanted to abandon further therapy after receiving information about the risk of complications (9 patients), or 4) the patient was recommended for other therapy (9 patients).
Of the patients who underwent embolization, 67 were male and 83 were female patients. They ranged in age from 5 to 70 years (35.5 ± 14.8 yr, mean± standard deviation [SD] ) at the time of embolization. They underwent 1 to 9 embolization procedures (2.2 ± 1.5, mean ± SD), with varying intervals from days to months. The AVMs were diagnosed 2.7 ± 4.4 years after the first symptoms. In most patients, the presenting events or symptoms that led to diagnosis were cerebral bleeding, epilepsy, and headache (Table 1) .
TABLE 1. Events or Symptoms from Arteriovenous Malformations Leading to Diagnosis
We used the Spetzler-Martin scale, which classifies the AVMs by size, location, and type of venous drainage, to facilitate comparison with surgically treated patients (26) . For example, Spetzler-Martin Grade 5 indicates an AVM with a diameter >6 cm that is localized to an eloquent area and drains into the deep venous system of the brain.
Definitions of full and partial treatment of patients
Patients who received full treatment had AVMs that were eliminated by embolization or by supplementary elective or emergency surgery. We also included patients with embolized AVMs who had been accepted for stereotactic radiation by independent institutions.
Patients who underwent partial treatment had AVMs that after embolization still had arteriovenous shunting. This group was not scheduled for further treatment aimed at total obliteration of the AVMs.
Embolization technique
In 95% of patients, the embolization was performed by injection ofN-butylcyanoacrylate (Histacryl Bleu; Melsungen AG, Melsungen, Germany) into the nidus of the AVM. The catheter used from 1987 through 1989 had a balloon with a calibrated leak, as described by Kerber (21) .
After 1989, a gradual change took place from a guidewire-guided microcatheter to a flow-guided microcatheter. Currently, all embolizations are performed with a flow-guided microcatheter (Magic; Balt, Montmorency, France).
N-Butylcyanoacrylate was used as the only embolic agent in 66.0% of our patients. It was used in combination with polyvinyl alcohol (PVA) in an additional 24.6% of patients. PVA alone was used in 5.3% of patients. In the remaining 4.1% of patients, N-butylcyanoacrylate or PVA was used in combination with polylene threads or Viñuela cocktail (a mixture of contrast medium, 
Complications of embolization
We studied the neurological or neuropsychological complications that occurred during the first 4 weeks after the embolization procedure. However, transitory symptoms that occurred <=3 weeks were excluded. The complications were graded according to the National Institutes of Health stroke scale (Table 2 ) (4). According to this scale, a slight complication corresponds to 0 to 1 point, a moderate complication to 2 to 5 points, and a severe complication to >5 points. In practice, a slight complication indicates a negligible influence on functional status, a moderate complication indicates a deterioration of functional status but usually no influence on lifestyle, and a severe complication indicates an influence on quality and conduct of life. 
Late outcome
The outcome of the treatment was assessed by complete and standardized examination by a neurologist (C.L.) of all surviving patients, with two exceptions. One patient refused to participate in the follow-up, but good information was provided by his wife. Another patient who had moved abroad was described by her parents.
The time lapse from last embolization to the clinical examination for late outcome is called observation or follow-up time. To describe the outcome, we used the following scale, slightly modified after Heros et al. (15) : Excellent, patient returned to previous lifestyle; Good, patient returned to previous lifestyle but with a minor deficit; Fair, because of a new deficit, patient could not return to previous lifestyle but could lead an independent life; Poor, because of a new deficit, patient is dependent on others for daily living; Death from embolization, death <=4 weeks after the treatment session; Death from AVM event, death directly related to AVM >4 weeks after the treatment session; Death from other cause, non-AVM-related death. This closely follows the definitions used by Heros.
In addition, assessment of headache, epilepsy, and neurasthenic symptoms was conducted.
Patients were asked this question at follow-up: Are the symptoms eliminated, or very much improved (--), somewhat improved (-), unchanged (±), somewhat worse (-), or very much worse (-)?
RESULTS
Most of the cerebral AVMs in this study corresponded to Spetzler-Martin Grade 3 (46.7%), Grade 4 (28.7%), and Grade 5 (8.7%) (Fig. 1 ). The AVM volume was >4 cc in most patients (Fig. 1) . Through embolization, we eliminated the AVMs in 20 patients and reduced the AVMs to a size suitable for combined treatment in 80 patients; the AVMs were simply reduced in 50 patients.
Supplementary treatment using a gamma knife was performed on 64 patients, mostly at Karolinska Hospital; the linear accelerator was used on 2 patients and surgical treatment was undertaken in 14 patients (2 patients were treated in an emergency situation).
Consequently, 100 patients were fully treated and 50 patients were partially treated (Table 3 ), Page 7 of 22 Ovid: Lundqvist: Neurosurgery, Volume 39(3).September 1996.460-469 11/13/2006 http://gateway.ut.ovid.com/gw2/ovidweb.cgi ranging in age from 5 to 70 years (35.5 ± 15.7 yr, mean ± SD) and 7 to 65 years (35.2± 13.1 yr, mean ± SD), respectively. The observation time was 0.1 to 7.3 years (2.9 ± 1.7 yr, mean ± SD) in all patients, 0.1 to 7.3 years (2.8 ± 1.8 yr, mean ± SD) in the fully treated group, and 0.4 to 6.9 years (3.1 ±1.7 yr, mean ± SD) in the partially treated (embolized) group.
TABLE 3. Treatment in 150 Patients with Arteriovenous Malformations
There were 38 patients with centrally located AVMs. Half of the AVMs were fully embolized, and one of those was totally obliterated by embolization. The mean Spetzler-Martin grade for this group was 3.9, compared to 3.3 for the whole study.
Complications
Two patients (1.3%) died as a result of embolization. Severe complications occurred in 10 patients (6.7%), moderate complications in 23 patients (15.3%), and slight complications in 26 patients (17.3%). The relation to full or partial treatment is shown in Table 4 . There was only one slight complication noted in the group with Spetzler-Martin Grade 1; in the remaining grades, the frequency of complications was not related to size and location of AVMs. However, more complications tended to result from centrally located AVMs; 2 patients (5.3%) experienced severe complications, 12 patients(31.6%) experienced moderate complications, and 3 patients (7.9%) experienced slight complications. In addition, one of the two patients who died as a result of complications had centrally located AVMs.
TABLE 4. Complications after Full and Partial Treatmenta
At assessment of outcome, 6 patients with severe complications had improved to the level of moderate complications and 12 patients had improved from the moderate to the slight level. No patient with complications deteriorated during the follow-up time. The consequences of severe and moderate complications are presented in terms of points on a status scale (Table 5 ). Cerebral bleeding occurred within minutes after embolization in one patient and after 8 hours in another and resulted in death in both patients. The cause of the severe complications was hemorrhage in four patients and ischemia in six patients. The cause of the moderate complications was hemorrhage in 4 patients, suspected hemorrhage in 1 patient, and ischemia in 18 patients.
The neurological deficit and functional status of severe and moderate complications are presented in Table 6 . At assessment of outcome, improvement was seen in all patients (one patient regained use of a hand, and four patients with severe complications had restored gait)( Table 5 ).
TABLE 6. Symptoms Caused by Moderate or Severe Complications of Embolization (Number of Patients)
Risk of cerebral bleeding A history of bleeding before embolization was given by 74 patients; 76 patients had no history of bleeding. The same distribution, 19 patients, respectively, was found in patients with centrally located AVMs. Twelve patients experienced cerebral bleeding during the observation time, 0.7 to 6.9 years (4.0 ± 2.0 yr, mean ± SD) from the last embolization to assessment of outcome (Table   7) .
TABLE 7. History of Bleeding Incidents Related to Bleeding after Last Embolizationa
The three bleeding incidents in the fully treated patients occurred in one patient 5 months after embolization before planned radiotherapy, in a second patient 6 months after embolization from an aneurysm on a feeding artery before planned surgical clipping, and in a third patient before supplementary elective surgery.
The bleeding incidents in nine patients who received partial treatment (two with centrally located AVMs) occurred after a mean observation time of 4.2 years and were unrelated to the history of bleeding. The incidence exceeds that expected from the natural course (Fig. 2) . Among the patients with centrally located AVMs, only one bleeding incident occurred during the follow-up period. Feeder or nidus aneurysms were seen in 43 patients before therapy. One of 19 patients with occluded aneurysms had one episode of cerebral bleeding during the observation time. In contrast, 7 of 22 patients with persistent aneurysms had bleeding incidents. Compared with patients without aneurysms after therapy, the risk of bleeding was significantly higher (P < 0.05).
Causes of death
Eleven of 150 patients died because of the following complications: 1) complications of embolization (2 patients); 2) cerebral bleeding as a consequence of supplementary planned surgery (1 patient); 3) cerebral bleeding ranging from 0.5 to 5.0 years (3.5 ± 1.9, mean ± SD) after embolization (6 patients, 2 of whom underwent surgical treatment 2 weeks after the bleeding incidents but died without regaining consciousness 1-2 mo later); 4) other causes (2 patients, 1 of whom died because of cancer, and 1 of whom had a long history of psychiatric illness and committed suicide). Four of the six patients who died as a result of spontaneous hemorrhage from the AVMs during the follow-up period had a history of cerebral bleeding, and one patient had centrally located AVMs.
Symptoms
Occurrence of headache, epilepsy, and neurasthenic symptoms, including disturbance of memory and concentration ability, and the influence of the treatment were analyzed (Table 8) . We found a significant improvement with respect to headache and epilepsy in patients who received both full and partial embolizations. Focal symptoms of causes other than hemorrhage were present in 18 patients. Most had stationary symptoms or episodes of deterioration. Two patients had progressive symptoms. During the observation time, two patients died, six patients had regression of symptoms, seven patients were stationary, and three patients experienced progression of symptoms resulting from complications. 
Late outcome
The result of the treatment in terms of influence on lifestyle, dependence, and death is shown in Table 9 . An excellent or good outcome was seen in 78% of patients who underwent full treatment and 70% of patients who underwent partial treatment. Death in relation to AVMs occurred in two patients (2%) who underwent full treatment and seven patients (14%) who were partially treated. The result of full and partial treatment related to Spetzler-Martin grades is shown in Tables 10 and 11 
DISCUSSION
The main question regarding what influence elimination or partial treatment of the AVMs has on the incidence of cerebral bleeding cannot be answered simply. However, no evidence was found in our study to contradict the finding of others that eliminated AVMs do not bleed. In patients who have undergone full treatment, many of the essential requirements for elimination with time were reached, in addition to those AVMs eliminated by embolization or supplementary surgery, but a risk of bleeding remained until late effects of stereotactic radiotherapy had eliminated the AVM.
The patients in our study seemed to have an unsatisfactory number of complications of embolization in comparison with similar studies (1) . One reason could be the higher SpetzlerMartin profile in our study. In a similar study with surgical elimination of AVMs, the outcome was comparable to that in corresponding fully treated patients with AVMs in our study. Most of those patients were considered by neurosurgeons to be unsuitable for surgical treatment (15, 23) .
In 14 patients with AVMs <4 cc in volume, we saw one complication with persistent symptoms, which turned out to be moderate at follow-up (see Part I of this study [29] ), indicating a low risk comparable with the very low morbidity of stereotactic radiation of small AVMs of the brain (27) . However, our study includes too few patients with small AVMs to express the risk factor as a percentage.
A comparison of complications between the patients who were embolized from 1987 through 1988 and 1992 through 1993 showed an apparent improvement (28) . Of the latter group, comprising 27 patients, 11% had moderate complications and there were no severe complications or deaths. Improved technique and embolization material could explain this development, but a more likely explanation is uniform management of the whole embolization procedure, including intensive care, with measures to achieve continuous low blood pressure. In our experience, avoidance of blood pressure peaks during the embolization procedure and for days after probably reduces the risk of complications from bleeding. As expected, embolization of centrally located AVMs results in most complications (16) , whereas AVMs of small size carry a low risk irrespective of the choice of therapy (15, 27) .
Of our patients who underwent partial embolization and experienced bleeding during the follow-up time, most had no history of prior bleeding incidents (Table 7) . In contrast, four of six patients who died as a consequence of spontaneous bleeding had a history of bleeding. For more reliable information, the follow-up time must be longer than in our study.
Small AVMs are considered to carry a higher risk of cerebral bleeding than larger ones, but we could not find such a relation in our study (18) . This can probably be explained by the selection of patients. Small AVMs that present with hemorrhage are assumed to be overrepresented for surgical treatment (7) .
Large AVMs, partially treated, account for the deviation from an expected natural risk of bleeding (Fig. 2 ). This implies a greatly increased risk in this subgroup, which is supported by Brown et al. (6) regarding risk of hemorrhage in nonruptured AVMs. Other studies do not confirm the association of large AVMs and risk of bleeding (13, 18) . The implication is that partial embolization of AVMs with large volumes could increase the risk of bleeding. However, data from Karolinska Hospital show a decreased risk of bleeding before stereotactic radiation has eliminated the AVM, which supports the view that partial embolization is valuable (20) . That the embolization was minimal in patients with spontaneous hemorrhage and a fatal outcome also supports this conclusion. In patients with centrally located AVMs, the late outcome did not deviate from that in the whole study, despite the increased frequency of moderate complications (Table 11 ). Others have also achieved good results by endovascular treatment of deep centrally located AVMs (16) .
Feeder and nidus aneurysms were shown to be predictors for cerebral bleeding, making it important to perform selective angiography before making a decision on treatment in patients with AVMs (5, 11) .
The estimation of epilepsy and headache during the follow-up time is based on recollection by patients of their experience of intensity and frequency. Epilepsy occurred in nearly half of the patients studied. The influence of treatment is discussed in only a few studies and with diverging results (8, 25) . This study indicates positive effects in both groups of patients (those who underwent full and partial embolizations). A more detailed analysis of the epilepsy related to embolization will be published later. Regarding headaches, an even clearer improvement was seen. Neuropsychological disturbances have been noted in only a few patients but can be an underrated consequence of treatment (12) .
In summary, patients with AVMs in eloquent areas or whose lesions are too extensive to be cured by stereotactic radiosurgery now have the possibility of obtaining elimination of their AVMs by embolization alone or in combination with other therapies. The indications for therapy must be weighed against not only the estimated risk of cerebral bleeding but also the risk of complications of treatment. Selective angiography is a decisive factor because of the information it yields about the prognosis of the natural course. Aneurysms, which are not detectable by ordinary angiography, as well as venous stenoses, carry a documented increased risk (1) . The decreased number of complications during the last years of the study also increases the indication for treatment (28) . Another reason to completely embolize AVMs, even if only partial embolization is expected, is the level of clinical symptoms (30) . In addition, improved embolization techniques and our experience provide reasons for a more aggressive approach to embolization; fewer patients would need to undergo partial embolizations, and more patients would have full embolizations.
Of 66 patients who were treated with a combination of embolization and stereotactic radiation, 44 received angiographic study at 2 years' follow-up. Angiograms showed elimination or near elimination (>90% reduction) of AVMs in 34 (78%) patients. Recanalization was not seen. To present the best treatment strategy, we must wait for more studies, including our current one, which is the second follow-up including angiographic results. Important concepts are mentioned in this article that are compatible with those reported in our series (1) . We also concur with the authors' analysis of the angioarchitecture and correlation with hemorrhage. Patients in whom they were able to close the intranidal, or pedicle, aneurysm were protected against hemorrhage. However, seven patients in whom they did not achieve this goal developed hemorrhages; two of the patients died. This again is compatible with our experience.
Also compatible with our experience are those patients in whom hemorrhage occurred after embolization. The outcome in this group, which may be caused by a very select group of patients with very difficult malformations, seems to be worse than the outcome after spontaneous hemorrhage. We also concur with the authors that the location of the malformation is less critical from an endovascular point of view than it is from a surgical point of view. Endovascular treatment aims to close the abnormality and preserve all normal arteries in the vicinity, regardless of location in an "eloquent" or "noneloquent" area. Therefore, location as a risk factor seems to be less critical for endovascular embolization. We also concur with the authors that the preliminary angiogram, showing the size of the malformation and presence of perforators as part of the supply to the malformation, will predict success for endovascular treatment.
The authors seem to have a higher complication rate than the rates reported in other series, but it is probably related to their more honest and more thorough analysis and neurological examination. The complications of all interventional neuroradiological procedures in large series such as this one may get lost in view of the fact that these series are comprehensive and are conducted over a long period of time (7 yr). In the last several years, the use of nonballoon-tipped catheters and flow-guided catheters has markedly decreased the complication rate because vessel perforation and rupture are related to trauma from balloons or guidewires. On the other hand, microcatheter gluing has also decreased because of the decreased concentration of NBCA in the mixture. Therefore, longer injections are now possible and bonding of the glue to the microcatheter and vessel wall has also been markedly decreased. This group of investigators also follows several of our concepts; anatomic guidelines are the most important predictors of potential hazards and neurological complications, reaching the nidus and preserving all normal vessels decreases the risk, and sodium amytal was not used as a"provocative" test and the outcome was very good. Therefore, the use of sodium amytal as an excuse for poor technique, lack of superselectivity, or lack of knowledge of anatomy is clearly established in this group of patients.
We also concur that the Spetzler-Martin classification is a surgical description of surgical skills and does not correlate with endovascular treatment. We do concur with the authors that we use this classification for the sake of comparison, because it is frequently requested by interventional neuroradiologists. Again, we do concur that this does not correlate with the difficulty of managing patients from an endovascular point of view. Furthermore, no matter how effective the embolization, we can only try to affect the "size" of the remaining malformations. However, no interventional procedure can change the location of the malformations, venous drainage, or, in reality, size. Therefore, the Spetzler-Martin classification is difficult to change with endovascular procedures. We also concur with the statement that in those patients in whom cure is not possible by either embolization or a combination of techniques, the aim of the embolization is a targeted approach in an attempt to close the"weakness" of the angioarchitecture of the malformation, such as intranidal aneurysms or aneurysms in the pedicle, or to reduce the pressure in the veins that have an outflow restriction (1) . We agree with the technique of embolization and, for the most
